Navigation Links
Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on 'Molecular Targets and Cancer Therapeutics' Demonstrate Superior Profile of S*BIO's Novel Anti-Cancer Drug SB939
Date:10/22/2008

SINGAPORE, Oct. 22 /PRNewswire/ -- S*BIO Pte Ltd today announced that multiple presentations of pre-clinical and early clinical data for its HDAC inhibitor SB939 will be made at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. The results demonstrate that the "best-in-class" pre-clinical profile of S*BIO's novel anti-cancer drug SB939 translates into the clinic.

"We are pleased to announce clinical data from the ongoing Phase 1 trials of our orally-active HDAC inhibitor SB939," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "The pharmacokinetic and pharmacodynamic data obtained with SB939 in patients with advanced cancers are consistent with the superior HDAC inhibitor profile that we have previously demonstrated in pre-clinical studies."

"We continue to develop SB939 in the clinic to gain additional data on its anti-cancer activity as well as to demonstrate further its good tolerability and superior oral PK/PD profile."

Poster No. 136

Discovery of SB939, an HDAC inhibitor with a superior pre-clinical profile

SB939 is a potent HDAC inhibitor with superior anti-tumor efficacy and tolerability in pharmacological cancer models. The drug candidate also has favourable ADME, safety and pharmaceutical properties resulting in high and dose-proportional exposure after oral dosing. SB939 has a prolonged duration of action and is enriched in tumor tissue which may contribute to its potent anti-tumor activity and "best-in-class" profile. The structure-activity relationships leading to the discovery of SB939 will be discussed.

Poster No. 83

A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor

A robust, sensitive and quantitative Western blot assay for measuring acetylated histone 3 in tissues has been developed to evaluate the target efficacy of SB939 and is currently being used to study PK/PD relationships in the ongoing Phase 1 clinical trials. These data demonstrate that the excellent PK/PD relationship observed in pre-clinical models is mirrored in patients with advanced solid malignancies.

Poster No. 413

A Phase 1 dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies

SB939 shows excellent linear and dose-dependent oral exposure. It has a good PK/PD relationship, as well as promising clinical activity with a manageable toxicity profile. The recommended Phase 2 dose has been selected.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. Its second compound, SB1518, commenced Phase1 clinical trials in 2008 and has received orphan drug designation from the U.S. FDA. A third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Aravis Venture, Novartis Bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com.


'/>"/>
SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Disaboom Announces Preliminary Third Quarter Results
2. Caterpillar Logistics Services Retirees Win a Preliminary Injunction Providing Them Premium-Free Retiree Healthcare
3. [video] Charles Fust, CEO of SinoFresh HealthCare, Inc. Discusses Preliminary Test Results From In Vivo Pilot Study on WallSt.nets 3-Minute Press Show
4. Preliminary Lineup Set for 4th Annual Stem Cell Summit
5. Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data
6. Misys Announces Preliminary Results for the Year Ended 31 May 2008
7. Longs Reports Preliminary June Retail Drug Store Sales
8. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
9. NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share
10. Longs Reports Preliminary May Retail Drug Store Sales
11. AVMA Declares Preliminary Victory on Farm Bill Provisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon Blue ... with doctors and hospitals to make transformative changes in how health care is ... minds this week in discussing breakthroughs in cellular medicine to treat disease. After ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® Citicoline is one ... Nominated in the Healthy Ageing category, Cognizin® is being considered for this prestigious ... division can include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose ...
(Date:4/28/2016)... ... April 28, 2016 , ... Amada Senior Care, premier provider of non-medical in-home ... – its San Antonio West location. Prior to entering the senior care industry, Amada ... opening of Amada San Antonio West will take place on Friday, April 29th. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration ... Collaborative Residency Network. The platform is scheduled to launch in July 2016 and ...
(Date:4/28/2016)... ... April 28, 2016 , ... Point ... miniature microphones and headsets announced today that the US Patent Office has approved ... into a structure. This innovative design creates a lightweight and modular audio headset ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
(Date:4/27/2016)... DELHI , April 27, 2016 ... CSR initiative to save newborns   ... hospital for women & newborns in collaboration with Breast Milk ... launched the first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR ... best nutritional food source for infants and should be available ...
Breaking Medicine Technology: